Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Other Urinary | Urinary Bladder
What is the purpose of this trial?
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.
Approximately 140 patients are anticipated to be enrolled across approximately 50 sites from North America and Europe.
- Ages18 years and older
- Trial withImmunomedics, Inc.
- Start Date06/01/2022
- End Date06/30/2023
- Last Updated07/29/2022
- Study HIC#2000023211